Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary shares of Oxford Immunotec Global PLC. The ordinary shares are listed on the NASDAQ Global Market under the symbol “OXFD.”

Headquartered near Oxford, United Kingdom, and in Marlborough, Massachusetts, Oxford is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for underserved immune-regulated conditions. 

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Derek Dostal and associates Paul J. Connell and Chris Van Buren. Partner Po Sit and associate Gil Savir advised on U.S. tax matters and partner Jonathan Cooklin and associate Dominic Foulkes advised on certain English tax law matters. The intellectual property and technology team included counsel David R. Bauer and associate Paul S. Lee. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post